Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Ahead of Print | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 13562 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
Search Again
 Back
 Table of Contents
 
 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Article Access Statistics
 Reader Comments
 Email Alert
 Add to My List
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed648    
    Printed35    
    Emailed0    
    PDF Downloaded123    
    Comments [Add]    

Recommend this journal

 
ARTICLE
Year : 1999  |  Volume : 41  |  Issue : 1  |  Page : 54-59

Risperidone In Schizophrenia


1 Director Professor, Sassson General Hospitals Campus, Pune 411 001, India
2 Maharashtra Institute of Mental Health, Sassson General Hospitals Campus, Pune 411 001, India
3 Medical & Regulatory Director, Janssen-Cilag, Chollerstrasse 38, CH -6300 Zug, Switzerland
4 Medical Director, Janssen-Cilag Pharmaceuticals, Johnson & Johnson Limited, 30 Forjett Street, Mumbai 400 036, India

Correspondence Address:
Vinod Mogre
Medical Director, Janssen-Cilag Pharmaceuticals, Johnson & Johnson Limited, 30 Forjett Street, Mumbai 400 036, India

Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 21455354

Rights and PermissionsRights and Permissions

Efficacy and safety of new antipsychotic agent-risperidone was evaluated in the confirmed schizophrenic patients of either sex, over 15 years of age. Of the 30 patients who entered the study, 27 completed the trial as per the protocol and only 3 dropped out, one was lost to follow up, the other was an uncooperative patient who pulled out of the trial due to moderate side effects while one patients withdrew the consent at his own free will. The significant improvements were seen in the broad range of symptoms of schizophrenia at various time points in the trial. The significant beneficial effect on negative symptoms was particularly obvious. The drug was well tolerated by most patients, and side effects, when reported, were mild. Even the extrapyramidal symptoms reported could be easily controlled with oral trihexyphenidyl hydrochloride. The exhaustive extrapyramidal symptom rating scale also did not show any worsening during risperidone therapy. The efficacy and safety profile of novel antipsychotic drug risperidone makes it a useful therapeutic agent in the broad range of patients with schizophrenia.



[PDF]*

        

Print this article         Email this article